Christopher Sweeney
Harvard University
CancerPathologyOncologyProstate cancerMedicine
What is this?
Publications 523
#1Myles Smith (Harvard University)H-Index: 85
#2Neeraj Agarwal (HCI: Huntsman Cancer Institute)H-Index: 37
Last. Christopher Sweeney (Harvard University)H-Index: 57
view all 9 authors...
#1Silke GillessenH-Index: 35
#2Gerhardt AttardH-Index: 60
Last. Noel W. ClarkeH-Index: 53
view all 72 authors...
9 CitationsSource
#1Emma H. Allott ('QUB': Queen's University Belfast)H-Index: 15
#2Ericka M. Ebot (Harvard University)H-Index: 5
Last. Lorelei A. Mucci (Harvard University)H-Index: 60
view all 20 authors...
Purpose:Statins are associated with lower risk of aggressive prostate cancer, but lethal prostate cancer is understudied and contributing mechanisms unclear. We prospectively examined statins and lethal prostate cancer risk in the Health Professionals Follow-up Study (HPFS), tested associations with molecular subtypes, and integrated gene expression profiling to identify putative mechanisms. Experimental Design:Our study included 44,126 men cancer-free in 1990, followed for prostate cancer incid...
#1Christian D. Fankhauser (UZH: University of Zurich)H-Index: 9
#2Christopher Sweeney (Harvard University)H-Index: 57
Last. J. M. Connors (Brigham and Women's Hospital)H-Index: 28
view all 3 authors...
#1Brandon Bernard (Harvard University)H-Index: 9
#2Colin Burnett (BU: Boston University)H-Index: 1
Last. Srikala S. Sridhar (Princess Margaret Cancer Centre)H-Index: 23
view all 5 authors...
BACKGROUND: An older age at the diagnosis of prostate cancer has been linked to worse prostate cancer-specific survival (PCSS). However, these studies were conducted before the approval of many life-prolonging drugs. This study was aimed at describing outcomes in a contemporary cohort of men diagnosed with de novo metastatic prostate cancer (mPCa) and assessing associations with the age at diagnosis while controlling for known prognostic factors. METHODS: The Surveillance, Epidemiology, and End ...
1 CitationsSource
#1Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
#2Daniel W. Bowles (University of Colorado Denver)H-Index: 19
Last. Charles Swanton (Francis Crick Institute)H-Index: 66
view all 14 authors...
Abstract Background Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. Patients and Methods MyPathway is an ongoing, multiple basket, open-label, non-rando...
3 CitationsSource
#1Emily Grist (UCL: University College London)
#2Marina A. Parry (UCL: University College London)
view all 20 authors...
153Background: The PAM50 gene expression classifier stratifies localized prostate cancer into luminal A/B and basal subtypes: luminal A have superior prognosis compared to luminal B and basal. Drug...
#1Praful Ravi (Harvard University)H-Index: 9
#2Neil E. Martin (Brigham and Women's Hospital)H-Index: 26
Last. Christopher Sweeney (Harvard University)H-Index: 57
view all 10 authors...
280Background: MRI is increasingly used in follow-up of men undergoing AS for localized prostate cancer. Large cohorts predating the MRI era have shown that the risk of disease progression or stopp...
#1Edoardo Francini (Sapienza University of Rome)H-Index: 13
#2Fang-Shu Ou (Mayo Clinic)H-Index: 8
Last. Steven P. Balk (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 75
view all 14 authors...
174Background: Docetaxel (D) and cabazitaxel (C) are standard chemotherapies for mCRPC. A reliable biomarker predictive of resistance to D or C is yet to be identified. We aimed to assess the assoc...